PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

PCSK9 inhibitors for acute coronary syndrome: the era of early implementation

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new cholesterol-lowering strategy, can decrease low-density lipoprotein cholesterol (LDL-C) levels by inhibiting PCSK9 and reducing the degradation of LDL receptors; thus, they are impacting the management of dyslipidemia to the pre...

Full description

Bibliographic Details
Main Authors: Hongzhen Chen, Xiaomin Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
PCSK9 inhibitors
acute coronary syndrome
coronary heart disease
early implementation
low-density lipoprotein cholesterol
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1138787/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1138787/full

Similar Items